Consider this scenario, depicted in Nature a few years ago. “It’s 2037, and a middle-aged person can walk into a health centre to get a vaccination against cardiovascular disease. The injection targets cells in the liver, tweaking a gene that is involved in regulating cholesterol in the blood. The simple procedure trims cholesterol levels and dramatically reduces the person’s risk of a heart attack”.Continue reading
Click the links below to discover Ddda, the exceptional enzyme that allows mitochondrial editing, and celebrate curiosity-driven research.
The Nature paper by Joseph Mougous and David Liu: “A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing”
The news: “Scientists make precise gene edits to mitochondrial DNA for first time”
The news and views: “Mitochondrial genome editing gets precise”
The editorial: “Mitochondrial genome editing: another win for curiosity-driven research”
COVID-19 overshadowed CRISPR’s advancements this year. The July issue of Nature Biotechnology keeps you up with the latest news and trends in genome editing, covering clinical testing, tools, patents, and more.
CRISPeR Frenzy asked Luigi Naldini of the San Raffaele Telethon Institute for Gene Therapy in Milan for comment on three studies published in June on the preprint server bioRxiv. The experiments were carried out independently by the groups of Kathy Niakan of the Francis Crick Institute in London, Dieter Egli of Columbia University in New York City, and Shoukhrat Mitalipov of Oregon Health & Science University in Portland. These findings heighten safety concerns about heritable genome editing (see the news item by Heidi Ledford in Nature). Below you can read Naldini’s thoughts.Continue reading
Victoria Gray is the first US patient treated with CRISPR for a genetic disorder. Don’t miss the interview she gave to NPR almost one year after the experimental treatment.
The idea is bold and seems to have worked fine. By using a DNA cutting enzyme to disrupt the X chromosome, researchers succeeded in distorting the sex ratio of offsprings, eventually leading to the all-male populations collapse. Andrea’s Crisanti and colleagues at the Imperial College London did it to caged Anopheles gambiae mosquitoes in their quest for a genetic strategy to beat malaria. Please see their paper in Nature Biotechnology and the Imperial College press release.Continue reading
Say hello to CARMEN: a massively multiplexed, Cas13-based technology for nucleic acid detection, out yesterday in Nature. Its name stands for Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids, and it allows us to test many amplified samples for the presence of many viral sequences by using miniaturized detection reactions that self-organize in a microwell array. Sars-Cov2 included.Continue reading
Researchers from all the life sciences are turning their attention to the pandemic, and the CRISPR community is no exception. The latest CRISPR Journal‘s editorial presents a few of the projects that are showing promise, and others are probably going on. Kevin Davies and Rodolphe Barrangou also comment on the cancellation or postponement of several key conferences in the next few months due to Covid-19, especially the CRISPR 2020 meeting in Paris. They applaud all the scientists who are battling this disease in myriad ways and promise: we’ll meet again.